Kymera Therapeutics Inc. Revenue 2019–2025
Kymera Therapeutics Inc. annual/quarterly revenue history and growth rate from 2019 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Kymera Therapeutics Inc. revenue for the quarter ending March 31, 2026 was 34.4 M, a 55.50% increase year-over-year.
- Kymera Therapeutics Inc. revenue for the twelve months ending March 31, 2026 was 70.7 M, a 59.22% increase year-over-year.
- Kymera Therapeutics Inc. annual revenue for 2025 was 39.2 M, a 16.70% decrease from 2024.
- Kymera Therapeutics Inc. annual revenue for 2024 was 47.1 M, a 40.11% decrease from 2023.
- Kymera Therapeutics Inc. annual revenue for 2023 was 78.6 M, a 67.84% increase from 2022.
- Kymera Therapeutics Inc. annual revenue for 2022 was 46.8 M.
Kymera Therapeutics Inc. (KYMR) — Frequently Asked Questions
Kymera Therapeutics Inc. (KYMR) is a publicly traded US company. It has a market capitalization of $6.99B. In fiscal 2025 it reported revenue of $39M and net income of -$311M. Explore KYMR's stock price, financial statements, earnings history, margins and key ratios below.
What is Kymera Therapeutics Inc.'s market cap?
Kymera Therapeutics Inc. (KYMR) has a market capitalization of $6.99B.
What is the KYMR stock price?
KYMR trades at $82.72 (+5.74% on the day).
How much revenue does Kymera Therapeutics Inc. make?
Kymera Therapeutics Inc. reported revenue of $39M in fiscal 2025.
Is KYMR profitable?
In fiscal 2025, Kymera Therapeutics Inc. reported net income of -$311M.